2024-12-11 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company, significantly underperformed the S&P 500 (VOO) over the measured period.  While JNJ showed a cumulative return of 27.57%, VOO achieved a cumulative return of 120.40%. This represents a substantial divergence of -92.8%, placing it at the 1.5th percentile of its historical range relative to the S&P 500.  The provided alpha values consistently hover around zero, suggesting the stock's performance is largely explained by market movements (beta).


**2. Recent Price Movement:**

* **Last Price:** $149.23
* **5-Day Moving Average:** $149.63
* **20-Day Moving Average:** $152.35
* **60-Day Moving Average:** $157.59

The stock price is currently below all three moving averages, indicating a possible short-term bearish trend.  The relatively small difference between the last price and the 5-day moving average suggests recent price stability.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 38.47 – Suggests the stock is currently in oversold territory.
* **PPO (Price Oscillator):** -0.18 – Indicates bearish momentum.
* **Recent Relative Divergence:** +1.5 – Shows short-term upward movement relative to the S&P 500.
* **Expected Return:** 0.0% – This indicates that, based on the provided data, no significant outperformance relative to the S&P 500 is expected over the long term (2+ years) given a consistent investment strategy.  The model suggests a lack of significant alpha.


**4. Recent Earnings Analysis:**

The recent earnings show fluctuating EPS and relatively stable revenue.

* **EPS Trends:** EPS shows considerable volatility across quarters, with a significant jump in the October 2023 quarter.  There is no consistent trend discernible from the provided data.
* **Revenue Growth Trends:** Revenue remains relatively flat over the past several quarters, indicating slow growth.
* **Quarter-over-Quarter Comparison:**  Revenue has fluctuated minimally, but no clear trend is observed.  EPS changes are more pronounced. The October 2023 EPS is notably higher than other quarters.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, while profit margins have fluctuated slightly, generally remaining above 68%.
* **Capital and Profitability:** Equity fluctuates, and ROE shows significant variation, peaking at a very high 36.54% in the September 2023 quarter. This suggests potential variability in profitability.


**6. News and Recent Issues:**

No specific news or analyst opinions within the last two days concerning JNJ's earnings was provided.  Therefore, an analysis of recent market outlook and analyst opinions is impossible based on the provided information.


**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 recently, showing a considerable negative divergence.  While the RSI suggests the stock might be oversold, the PPO and moving averages indicate bearish momentum. Earnings show some volatility in EPS, but relatively stable revenue.  The high variance in Return on Equity needs further investigation. The provided data does not support a strong case for outperformance against the market. Further research is needed, particularly involving a review of the exceptional ROE in the September 2023 quarter and news affecting the company's performance. The lack of recent news and analyst opinions limits the scope of this analysis. A more complete picture would require access to additional financial data, market sentiment analysis, and recent news releases.  The 0% expected return should be viewed cautiously, as it's based on limited historical data and does not account for potential future market shifts or unforeseen company developments.


**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Consult with a qualified financial advisor before making any investment decisions.
